Plasmid mediated ghrh supplementation for renal failures
CA 2563312 C · Owner: Draghia-Akli, Ruxandra · Inventors: Brown, Patricia A.; Draghia-Akli, Ruxandra; Scott, Clara
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention pertains to compositions and methods for plasmidmediated supplementation. The compositions and methods are useful for treatment or prevention of kidney failure treatment of anemia, and other , conditions commonly associated with kidney failure in order to increase survival and improve welfare in subjects with chronic renal failure. Overall the embodiments of the invention can be accomplished by delivering an isolated nucleic acid expression construct that encodes a GHRH or functional biological equivalent thereof into a tissue of a subject and allowing expression of the encoded gene in the animal. For example when such a nucleic acid sequence is , delivered into …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 20, 2004 and granted January 14, 2014. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 20, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 20, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.